Astaxanthin

What astaxanthin is

Astaxanthin belongs to the xanthophylls, a subgroup of carotenoids. The alga Haematococcus pluvialis forms it under stress and turns deep red in the process; via the food chain it ends up in salmon, trout, shrimp and krill. It differs from beta-carotene by additional oxygen groups at both ends of the molecule and thus spans across cell membranes instead of merely floating in their fatty core. From this, manufacturers derive the narrative that it protects membranes from the inside and outside at the same time.

Where the vitamin C figure comes from

Marketing routinely calls astaxanthin several hundred times stronger than vitamin C. The figure has a concrete origin. In 2007, Nishida, Yamashita and Miki measured in Carotenoid Science how quickly various antioxidants scavenge singlet oxygen. The total quenching constants were 5.4 for astaxanthin, 0.049 for alpha-tocopherol and 0.00089 for L-ascorbic acid, each in the unit 10 to the power of 9 per mole and second.

Two things about this are important. First, the paper itself does not state any multiplication factor; the advertised figure only arises when someone divides two table values by each other. Second, this was an assay in an organic solvent mixture, without cells, without blood, without digestion. An older measurement by Miki gives the advantage over vitamin E as more than 100-fold. None of these figures says how much of it reaches tissue. This is exactly where the marketing stops being clean.

Skin: moisture and elasticity, not wrinkles

This is where the best finding lies. A systematic review pooled 8 randomized controlled trials with 162 participants in the astaxanthin groups and 131 in the placebo groups, 2 to 12 mg daily over 4 to 16 weeks. Skin moisture improved with a standardized mean difference of 0.53 (p = 0.03), elasticity with 0.77 (p = 0.009).

The endpoint advertised most loudly failed. Wrinkle depth did not change: -0.26, confidence interval -0.58 to 0.06, p = 0.11. Notable is the heterogeneity of 0 percent — the studies agree that there is nothing there. On UV protection, a double-blind study in 23 participants found an increased minimal erythema dose after 9 weeks with 4 mg daily, whereas a meta-analysis of 40 randomized trials found no benefit for carotenoids as a group.

Endurance and recovery

A meta-analysis of 24 randomized controlled trials cleanly separates two questions. Creatine kinase, a marker of muscle damage, fell significantly: -0.45, confidence interval -0.83 to -0.07. Lactate dehydrogenase also fell (-0.93), albeit with considerable variation between the studies.

Performance itself remained unchanged. Maximal oxygen uptake, time-trial performance and maximal workload showed no significant improvement. Consistent with this, a study in 24 active men with 12 mg and 36 mg daily over 4 weeks lowered creatine kinase equally, with no difference between the amounts and no effect on muscle soreness. The International Society of Sports Nutrition nevertheless counts astaxanthin in the range of 4 to 12 mg among the best-supported antioxidants for recovery.

Eyes and metabolism

For the eyes, the studies are not about blue-light filtering but about screen fatigue. A double-blind study in 64 children aged 10 to 14 found, after 84 days with 4 mg daily, a decrease in the symptom score of 4.00 points versus 1.72 under placebo. A study in 60 adults with 9 mg over 6 weeks found the protective effect on visual acuity only in participants aged 40 and over.

For metabolism, there is a meta-analysis of 9 studies with 403 patients with prediabetes and type 2 diabetes: fasting blood sugar fell by 16.126 mg/dl, glycated hemoglobin by 0.338, along with total cholesterol and LDL. It had no effect on body weight and insulin resistance.

What the studies show

Skin aging: the finding and the gap in it

Systematic review of 11 studies, of which 8 randomized controlled trials were pooled, 6 of them double-blind. There, 162 participants in the astaxanthin groups faced 131 participants in the placebo groups, with 2 to 12 mg daily over 4 to 16 weeks. Moisture and elasticity improved significantly, wrinkle depth did not. The authors themselves name two weaknesses: fewer than 10 pooled studies, each with under 100 participants, and part of the work was funded by commercial entities.

Exercise and recovery: 24 studies, a clear dividing line

Meta-analysis of 24 randomized controlled trials in healthy people and athletes, literature search up to January 2026. Performance endpoints were tested on the one hand, recovery markers on the other. The result separates the two: creatine kinase significantly lowered, lactate dehydrogenase too, but with considerable variation, malondialdehyde and interleukin-6 unchanged. None of the three performance endpoints was met. The authors conclude that astaxanthin benefits recovery rather than the exertion itself.

UV protection: a small study against a large analysis

The only paper found that measures UV protection directly by the minimal erythema dose is double-blind and placebo-controlled, but includes only 23 participants over 10 weeks with 4 mg daily. After 9 weeks, the erythema dose was increased and moisture loss in the irradiated area was lower. Against this stands a meta-analysis of 40 randomized trials in which carotenoids as a group had no effect.

Where the data stop

The order of disappointments follows the order of the advertising promises. Wrinkle depth does not move, consistently across all studies. Endurance performance does not move, even though 24 randomized trials looked for it. And blue-light protection cannot be tested with the available studies at all: they measure symptoms of screen fatigue, not light filtering. The human macular pigment consists of lutein, zeaxanthin and meso-zeaxanthin. EFSA rejected 15 health claims applied for, including those on eyes, joints and the immune system.

The antioxidant effect, too, is not stable across all markers. The same analysis that markedly lowers oxidized plasma proteins finds no significant changes in malondialdehyde, superoxide dismutase, thiol groups and interleukin-6. In a study in 80 patients with heart failure, TNF-alpha and MCP-1 fell, but high-sensitivity C-reactive protein did not. Then there is the structural limit: almost all endpoints are surrogate markers, the studies are small and run for weeks. None of the papers found tested hard endpoints such as skin cancer incidence or vision loss. For the claim that astaxanthin crosses the blood-brain and blood-retina barriers in humans, no human measurement was found.

Status, approval and legal

In the EU, astaxanthin is considered a novel food and may only be used in authorized forms and amounts. Authorized are, among others, the oleoresin from the microalga Haematococcus pluvialis and oil from the copepod Calanus finmarchicus. The maximum amounts are graded by age: from the algal oleoresin 2.3 mg daily for 3- to 10-year-olds, 5.7 mg for 10- to 14-year-olds and 8 mg from age 14, from the Calanus oil 2.25 mg, 5.5 mg and 7.75 mg; for children under 3 not at all. There is no health-related advertising claim; EFSA rejected 15 claims applied for. There is no marketing authorization as a medicine for any indication, and astaxanthin does not appear on the 2026 WADA Prohibited List.

Safety

In 2020, EFSA based its assessment on a daily reference value of 0.2 mg per kilogram of body weight, which replaced an older value of 0.034 mg, and classified 8 mg daily from food supplements in addition to the normal diet as safe for adults. For younger age groups the picture is different: adolescents aged 14 to under 18 reach the reference value, in children aged 10 to under 14 it is exceeded by 28 percent, in infants aged 4 to 6 months by up to 524 percent. Individual products contain up to 18 mg per serving. It is advised against in pregnancy and breastfeeding due to missing data and during cancer therapy, because antioxidants can weaken chemotherapy and radiotherapy. An influence on cytochrome P450 enzymes is possible; krill products can be a risk with a shellfish allergy. The International Agency for Research on Cancer sees no increased cancer risk.

Sources

• Zhou et al., Nutrients 2021 — meta-analysis on skin aging
• Liu et al., Nutrients 2026 — meta-analysis on recovery and performance
• You et al., 3 Biotech 2026 — meta-analysis on exercise-induced oxidative stress
• EFSA NDA Panel, EFSA Journal 2020 — safety of astaxanthin as a novel food
• Ito, Seki, Ueda, Nutrients 2018 — UV protection and minimal erythema dose
• Yang et al., Frontiers in Medicine 2025 — meta-analysis on supplements and skin photoaging
• Molani-Gol et al., Nutrition and Metabolic Insights 2026 — meta-analysis on blood sugar and blood lipids
• Hecht et al., Advances in Therapy 2025 — RCT on digital eye strain in children
• Gonzalez et al., J Int Soc Sports Nutr 2026 — ISSN position stand on antioxidants in sport
• Verbraucherzentrale (German consumer advice center) — astaxanthin, novel food status and maximum amounts